The newest urology products and services from Covidien, Beckman Coulter, Inc., Allergan Inc., the Seattle App Lab, and Griffin Technology.
Knotless suture device increases operating room efficiency
For more information, visit http://www.covidien.com/.
Irvine, CA-Allergan Inc. recently introduced a new online resource for urologists to offer their urinary incontinence (UI) patients. The Web site provides easy-to-understand explanations of UI due to detrusor overactivity associated with a neurologic condition, video interviews with patients and doctors, free resources, and information on onabotulinumtoxinA (Botox) as a treatment option for patients who have an inadequate response to or cannot tolerate the side effects of an anticholinergic medication.
For more information, visit http://www.botoxforincontinence.com/.
FDA approves new blood test to improve PCa detection
For more information, visit http://www.beckmancoulter.com/.
iPhone app allows Peyronie's patients to track deformity
Seattle-A mobile diagnostic iPhone app called Peyronie's Disease Diagnostic Tool has been developed by the Seattle App Lab. Developed for the University of Washington's urology department, the app allows patients to track penile deformity by auto-photography transmitted to their physicians. By allowing men to characterize the deformity at home, the app may avoid the need for costly and invasive tests, according to Seattle App Lab. Slated for release in August, the app will be available in the Apple Store for free iPhone and iPad downloads.
For more information, visit http://www.seattleapplab.com/.
Sanitizable iPad case allows for usage when wearing gloves
For more information, visit http://www.griffintechnology.com/.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.